Effects of Glucagon-Like Peptide-1 Receptor Agonists on Weight Loss in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis

Table 1

Characteristics of the studies included in the network meta-analysis.

Number	Study ID	Investigational treatments	Size	Therapy duration	Baseline information
					Age	Course of T2D
1	Apovian CM, 2010	EX10BID, placebo	142	24	54.8	5.5	7.6
2	Arnolds S, 2010	EX10BID, placebo, and sitagliptin	48	4	56.5	5.5	8.2
3	Barnett AH, 2007	EX10BID, insulin	276	16	54.9	7.4	9
4	Bergenstal R, 2009	EX10BID, insulin	248	24	52.2	8.5	10.2
5	Bunck MC, 2009	EX10BID, insulin	69	52	58.3	4.9	7.5
6	Buse JB, 2004	EX5BID, EX10BID, and placebo	377	30	55	6.3	8.6
7	Buse JB, 2011	EX10BID, placebo	259	30	59	12	8.4
8	DURATION-1, Drucker DJ, 2008	EX10BID, EX2QW	295	30	55	6.5	8.3
9	DURATION-2, Bergenstal RM, 2010	EX2QW, sitagliptin, and TZD	491	26	52.5	6	8.6
10	DURATION-3, Diamant M, 2012	EX2QW, insulin	466	84	58	7.9	8.3
11	DURATION-4, Russell-JonesD, 2012	EX2QW, sitagliptin, Met, and TZD	820	26	53.8	2.7	8.5
12	DURATION-6, Buse JB, 2013	EX2QW, LIR1.8	802	26	57	—	8.5
13	Davies M, 2013	EX2QW, insulin	194	26	58.5	—	8.4
14	Davies MJ, 2009	EX10BID, insulin	204	26	56.5	8.7	8.6
15	Davis SN, 2007	EX10BID, insulin	45	16	53	11	8.1
16	DeFronzo RA, 2005	EX5BID, EX10BID, and placebo	336	30	53	5.8	8.2
17	DeFronzo RA, 2010	EX10BID, TZD	88	20	56	4.7	7.8
18	Derosa G, 2010	EX10BID, SU	116	52	56.5	—	8.9
19	Derosa G, 2011	EX10BID, SU	101	52	55.5	—	8.8
20	Derosa G, 2012	EX10BID, placebo	171	48	57.0	7.7	8.0
21	Forst T, 2012	LIR1.8, placebo	40	12	55.1	3.8	6.3
22	Gallwitz B, 2011	EX10BID, insulin	354	26	57	5	7.9
23	Gallwitz B, EUREXA, 2012	EX10BID, SU	386	234	56	5.8	—
24	Gao Y, 2009	EX10BID, placebo	466	16	54.5	8	8.3
25	Harder H, 2004	LIR0.6, placebo	33	8	60	4.1	7.5
26	Heine RJ, 2005	EX10BID, insulin	535	26	58.9	9.6	8.2
27	Inagaki N, 2012	EX2QW, insulin	426	26	56.76	9.03	8.5
28	Iwamoto K, 2009	EX2QW, placebo	19	10	58	6	7.4
29	Ji LN, 2013	EX10BID, EX2QW	574	26	55	—	—
30	Kadowaki T, 2009	EX5BID, placebo, and EX10BID	114	12	60.3	11.8	8
31	Kadowaki T, 2011	EX5BID, EX10BID, and placebo	178	24	58.4	12	8.2
32	Kaku K, 2010	LIR0.9, LIR0.6, and placebo	264	52	59.7	10.3	8.4
33	Kendall DM, 2005	EX5BID, EX10BID, and placebo	733	30	55.3	8.9	8.5
34	Kim D, 2007	EX2QW, placebo	29	15	54	5	8.5
35	LEAD-1 Marre M, 2009	LIR1.2, LIR0.6, LIR1.8, TZD, and placebo	1041	26	56.1	6.5	8.4
36	LEAD-2 Nauck M, 2009	LIR1.2, LIR0.6, LIR1.8, SU, and placebo	1077	104	57	7.9	8.4
37	LEAD-3 Garder A, 2011	LIR1.2, LIR1.8, and SU	733	104	53	5.4	8.3
38	LEAD-4 Zinman B, 2009	LIR1.2, LIR1.8, and placebo	533	26	55	9	8.5
39	LEAD-5 Russell-Jones D, 2009	LIR1.8, insulin, and placebo	576	26	57.6	9.4	8.3
40	LEAD-6-Buse JB, 2009	EX10BID, LIR1.8	464	26	56.7	8.2	—
41	Liutkus J, 2010	EX10BID, placebo	165	26	54.7	6.4	8.2
42	Moretto TJ, 2008	EX5BID, EX10BID, and placebo	232	24	54	2	7.8
43	NCT00620282, 2011	LIR1.8, SU, and placebo	47	12	58.5	6.8	7.2
44	NCT00701935, 2013	EX10BID, placebo	75	24	58.2	57.9	—
45	Nauck MA, 2007	EX10BID, insulin	501	52	58.5	9.9	8.6
46	Pratley R, 2011	LIR1.2, LIR1.8, and sitagliptin	644	52	55.3	6.2	8.4
47	Seino Y, 2008	LIR0.6, LIR0.9, and placebo	135	14	57	8	8.3
48	Seino Y, 2010	LIR0.9, SU	400	52	58.3	8.3	8.9
49	Yang W, 2011	LIR0.6, LIR1.2, LIR1.8, and SU	907	16	53.3	7.5	8.5
50	Yuan GH, 2012	EX10BID, Met	59	26	50.5	<1 month	8.2
51	Zinman B, 2007	EX10BID, and placebo	233	16	56	8	7.9

Note: LEAD: liraglutide effect and action in diabetes; DURATION: diabetes therapy utilization: researching changes in HbA_1c, weight, and other factors through intervention with exenatide once weekly; EX5BID: exenatide 5 μg twice daily; EX10BID: exenatide 10 μg twice daily; EX2QW: exenatide 2 mg once weekly; LIR0.6: liraglutide 0.6 mg once daily; LIR0.9: liraglutide 0.9 mg once daily; LIR1.2: liraglutide 1.2 mg once daily; LIR1.8: liraglutide 1.8 mg once daily; SU: sulfonylureas; TZD: thiazolidinediones; Met: metformin. —: unavailable information.